Each week Collective IP highlights a particular profile, either a company, an investigator or technology transfer office. Today we shine the light upon Columbia University:
A leading academic and research university, Columbia University continually seeks to advance the frontiers of knowledge and to foster a campus community deeply engaged in understanding and addressing the complex global issues of our time. Founded in 1754 as King’s College, Columbia University in the City of New York is the fifth oldest institution of higher learning in the United States.
Columbia Technology Ventures (CTV) is widely regarded as one of the most experienced and successful technology transfer offices in the world, with more than 350 invention disclosures from faculty and more than 70 license deals each year. Since its founding in 1982, Columbia has managed over 5,700 inventions, over 3,000 worldwide patents, and has been among the top university generators of licensing revenue in the world. CTV currently has over 1,200 patent assets available for licensing, across research fields such as bio, IT, cleantech, devices, nanotechnology, and material science.
Over the years, CTV has launched over 150 companies based on Columbia’s technologies. Of these companies, over 40 have received VC funding, with 27 successful acquisitions or IPOs to date.
Columbia technologies are behind many successful therapeutic drugs, including Xolinza®, Remicade®, Xalatan®, and medical devices, such as the Arrow® catheter and the Bigliani- Flatow® Shoulder, to name a few.